8 hasil untuk "Gibb, Adam"
Menampilkan 1–8 · 0,37 detik · RSS
-
Artikel Jurnal Teks lengkap
Gamma–delta T-cell lymphoma of skin, eye and brain presenting with visual loss
A young man presented with rapid, predominantly right-sided visual loss with a background of multifocal skin lesions. Visual acuity was right hand movements, left 6/5 Snellen, deteriorating to 6/38. He showed panuveitis with bilateral multifocal retinal infiltrates and retinal vasculitis…
-
Artikel Jurnal Teks lengkap
Bilateral adrenal masses and adrenal insufficiency: a rare case of primary adrenal lymphoma
SUMMARY: Primary adrenal lymphoma (PAL) is a rare malignancy typically considered in patients presenting with features of adrenal insufficiency and bilateral adrenal gland enlargement. Early diagnosis and differentiation from other causes of bilateral adrenal masses are essential to guide…
-
Artikel Jurnal Teks lengkap
Brentuximab vedotin in refractory CD30(+) lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
The CD30-targeted agent brentuximab vedotin has shown impressive activity in relapsed/refractory Hodgkin lymphoma and anaplastic large cell lymphoma in phase II studies. We have treated 24 patients with relapsed/refratory disease enrolled onto a Named Patient Programme during 2010-11 at a single UK…
-
Artikel Jurnal Teks lengkap
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
-
Artikel Jurnal Teks lengkap
Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture are both more common in older patients. Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evidence is lacking to define fracture incidence in…
-
Artikel Jurnal Teks lengkap
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience
Bendamustine is among the most effective chemotherapeutics for indolent B-cell non-Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a multicenter observational study evaluating…
-
Artikel Jurnal Teks lengkap
Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy
Over 60% of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy and information in this setting is scarce and heterogeneous. We analyzed 387 R/R LBCL…
-
Artikel Jurnal Teks lengkap
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study()
During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy…